Investec Asset Management North America Inc. increased its stake in Agilent Technologies Inc (NYSE:A) by 45.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,255 shares of the medical research company’s stock after purchasing an additional 5,069 shares during the quarter. Investec Asset Management North America Inc.’s holdings in Agilent Technologies were worth $1,307,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Captrust Financial Advisors lifted its holdings in Agilent Technologies by 2,121.1% in the 4th quarter. Captrust Financial Advisors now owns 422 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 403 shares during the last quarter. Lake Point Wealth Management acquired a new stake in Agilent Technologies in the 4th quarter valued at about $30,000. JOYN Advisors Inc. lifted its holdings in Agilent Technologies by 186.6% in the 4th quarter. JOYN Advisors Inc. now owns 470 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 306 shares during the last quarter. Truehand Inc acquired a new stake in Agilent Technologies in the 4th quarter valued at about $33,000. Finally, We Are One Seven LLC acquired a new stake in Agilent Technologies in the 4th quarter valued at about $33,000.
A number of brokerages have weighed in on A. Deutsche Bank reissued a “buy” rating and issued a $90.00 price target on shares of Agilent Technologies in a report on Thursday, February 21st. Cowen upped their price target on shares of Agilent Technologies from $80.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Barclays upped their price target on shares of Agilent Technologies from $80.00 to $83.00 and gave the company an “overweight” rating in a report on Thursday, February 21st. Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $82.00 price objective (up from $77.00) on shares of Agilent Technologies in a research note on Wednesday, February 20th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $87.17.
Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.03. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The company had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period in the prior year, the firm earned $0.66 earnings per share. The business’s quarterly revenue was up 6.0% on a year-over-year basis. Sell-side analysts predict that Agilent Technologies Inc will post 3.06 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd were paid a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend was Monday, April 1st. Agilent Technologies’s dividend payout ratio is presently 23.66%.
In related news, SVP Michael Tang sold 6,728 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $80.50, for a total value of $541,604.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael R. Mcmullen sold 17,491 shares of the stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $75.00, for a total value of $1,311,825.00. Following the completion of the transaction, the chief executive officer now owns 456,430 shares in the company, valued at approximately $34,232,250. The disclosure for this sale can be found here. Insiders have sold 83,722 shares of company stock valued at $6,532,504 over the last ninety days.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Read More: What is the Ex-Dividend Date in Investing?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.